Sunshine Biopharma Receives Notice of Allowance for a New Patent Application Extending Protection of Adva-27a Anticancer Drug Until 2033 – Press Release – Digital Journal

Sunshine Biopharma Receives Notice of Allowance for a New Patent Application Extending Protection of Adva-27a Anticancer Drug Until 2033 – Press Release  Digital Journal

“We are very excited about this significant development for Adva-27a,” said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. “Allowance of the second …